
-
Indian capital bans fuel for old cars in anti-pollution bid
-
Flintoff rules himself out of top England coaching job
-
Russia ramps up drone strikes on Ukraine in June: AFP analysis
-
Japan had hottest June on record: weather agency
-
Asian stocks rise on trade deal hopes, Tokyo hit by Trump warning
-
Thailand's PM suspended by Constitutional Court
-
Blur will return to musical oasis, says drummer Rowntree
-
CBEX crypto scam: AI-hyped Ponzi scheme defrauds African investors
-
Inzaghi hails 'extraordinary' Al Hilal after City upset
-
Man City, Inter Milan crash out of Club World Cup in last 16
-
North Korea's Kim shown honouring troops killed in Russia-Ukraine war
-
Saudi's Al Hilal knock Man City out of Club World Cup in huge shock
-
'In our blood': Egyptian women reclaim belly dance from stigma
-
Online memorial for children dead in Hiroshima, Nagasaki
-
US Senate in final push to pass Trump spending bill
-
Asian stocks rise on trade deal hopes, Tokyo hit by tariff warning
-
Hong Kong rights record under fire as it marks China handover anniversary
-
Bangladeshis cling to protest dreams a year after revolution
-
Djokovic, Sinner enter Wimbledon fray
-
European security tops Denmark's EU presidency priorities
-
France expecting peak temperatures as heatwave hits Europe
-
Germany eye return to women's football summit at Euro 2025
-
'Every day I see land disappear': Suriname's battle to keep sea at bay
-
England feel pressure to perform at Euros as stars pull out
-
Clashes in Istanbul over alleged 'Prophet Mohammed' cartoon
-
India face 'last-minute' Bumrah call as they bid to level England series
-
Dortmund up against 'superstar' Ramos, aggressive Monterrey: Kovac
-
US judge orders Argentina to sell 51% stake in oil firm YPF
-
DEA BUSTED!! While Chinese Marijuana Cartels Spread Right Under DEA's Nose, FDA CANNABIS RESEARCH BLOCKED
-
Proenkephalin A 119-159 (penKid) Leads the Way in Predicting Graft Outcomes for Kidney Transplant Recipients
-
DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement
-
Record Financing for NeXtWind: €1.4 Billion for the Expansion of Wind Energy in Germany
-
Pantheon Resources PLC Announces Change of Registered Office
-
EPA employees accuse Trump administration of 'ignoring' science
-
US Senate in final slog towards vote on Trump spending bill
-
Over 14 million people could die from US foreign aid cuts: study
-
End of the line for Britain's royal train
-
FIFPro warns of 'wake-up call' over extreme heat at Club World Cup
-
Sean Combs sex trafficking jury ends first day without decision
-
Fluminense stun Inter Milan to reach Club World Cup quarters
-
Thailand's ruling political dynasty faces day of legal peril
-
NASA eyes summer streaming liftoff on Netflix
-
Trump dismantles Syria sanctions program as Israel ties eyed
-
Meta's AI talent war raises questions about strategy
-
Twenty bodies, some headless, found in Mexican cartel bastion
-
Gaza rescuers say Israeli forces kill over 50 as ceasefire calls mount
-
Alcaraz survives scare, Sabalenka cruises on Wimbledon's hottest opening day
-
Only Messi can shirk defending: warns Monterrey coach before Dortmund clash
-
White House says Canada 'caved' to Trump on tech tax
-
Eight-country coalition aims to tax luxury air travel

US panel recommends nonprescription use of contraception pill
A US panel of health experts voted Wednesday in favor of making birth control pills available without a prescription, a move backed by reproductive rights advocates especially in the wake of a Supreme Court ruling overturning the national right to abortion.
The independent panel voted unanimously that the benefits of allowing the medicine, Opill, to be sold over the counter, outweighed the risks and would reduce hurdles associated with visiting a doctor that impact lower income groups disproportionately.
"I believe that the efficacy and safety of this birth control form was established over half a century ago," said panelist Jolie Haun of the James A. Haley Veterans' Hospital.
"We now have been presented with ample data demonstrating the effective safe use and benefits for people who want to have access to reproductive autonomy."
The committee's votes are usually accepted by the Food and Drug Administration, which means the pill, which is made by HRA Pharma, might be available without prescription in the coming weeks.
While likely, approval is not assured. FDA scientists highlighted safety concerns, such as the potential impact on people with a history or current diagnosis of breast cancer, or whether they would understand the pill needs to be taken the same time every day to prevent pregnancy.
"There is also concern that some consumers may not consistently use the product correctly on a chronic basis and be at risk for pregnancy, but not recognize that they are pregnant because of the irregular bleeding that would be ascribed to the known side effect," the FDA wrote in a document.
The push for a non-prescription pill has taken on new urgency in light of a Supreme Court decision overturning the constitutional right to abortion, leading to numerous bans and severe restrictions in conservative states.
It has received support from health groups such as the American Medical Association and American College of Obstetricians and Gynecologists.
If the pill is approved, the US would join more than 100 other countries where the pill is available without a prescription, including the UK which requires a consultation with a pharmacist.
Opill is known as a "mini pill" because it contains progestin only.
Another company, Cadence, is in talks with the FDA about making its combination pill, which contains both estrogen and progestin, available over the counter.
P.Martin--AMWN